Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis
References (36)
Facts and Statistics About Osteoporosis and Its Impact
- et al.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
N Engl J Med.
(2007) - et al.
Zoledronic acid and clinical fractures and mortality after hip fracture
N Engl J Med.
(2007) - et al.
Alendronate and atrial fibrillation
N Engl J Med.
(2007) - et al.
Yearly zoledronic acid in postmenopausal osteoporosis
N Engl J Med.
(2007) - et al.
Use of alendronate and risk of incident atrial fibrillation in women
Arch Intern Med.
(2008) - et al.
Relation of bisphosphonate therapies and risk of developing atrial fibrillation
Am J Cardiol.
(2009) - et al.
Atrial fibrillation in fracture patients treated with oral bisphosphonates
J Intern Med.
(2009) - et al.
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: Population based case-control study
BMJ.
(2008)
Bisphosphonates: Atrial fibrillation
Drug Safety Update
Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis
Drug Saf.
Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates
Mortality, disability, and nursing home use for persons with and without hip fracture: A population-based study
J Am Geriatr Soc.
Changes in functional status attributable to hip fracture: A comparison of hip fracture patients to community-dwelling aged
Am J Epidemiol.
Association between low bone density and stroke in elderly women. The study of osteoporotic fractures
Stroke.
Bone changes and carotid atherosclerosis in postmenopausal women
Stroke.
Bone mineral density and aortic calcification: The Study of Osteoporotic Fractures
J Am Geriatr Soc.
Cited by (44)
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
2020, Journal of Bone OncologyCitation Excerpt :Within this context, it is important to note that patients diagnosed with bone metastases limited to the skeleton often have a prolonged disease course [16,17] and up to 20% of patients with metastatic bone disease survive for more than 5 years [17]. Physicians must, therefore, consider the implications of cumulative BTA dosing, as the risk of BP-related adverse events (such as hypocalcemia, renal toxicity, osteonecrosis of the jaw, atypical fractures and vascular events [18–24]) have been shown to be directly proportional to both drug potency and cumulative dose [25]. To balance this, the potential implications of BTA discontinuation must also be taken into account, as multiple rebound fracture events have been reported following the cessation of denosumab [26].
Adverse cardiovascular effects of nitrogen-containing bisphosphonates in patients with osteoporosis: A nationwide population-based retrospective study
2016, International Journal of CardiologyCitation Excerpt :This could cause predisposition to Af [24–26]. Some clinical investigations of zoledronate, risedronate, and alendronate indicated no significant differences from the placebo in terms of the overall incidence of Af [27,28]. The high risk levels associated with BPs reported in prior studies have been attributed to confounding factors such as older age, more cardiovascular diseases, and COPD [29–31].
Characteristics of subsequent contralateral proximal femoral fracture: more convenient access is needed to treat osteoporosis
2023, Journal of Orthopaedic Surgery and ResearchCardiovascular Calcification Heterogeneity in Chronic Kidney Disease
2023, Circulation Research